Targeted breast cancer treatment approved

Women with advanced breast cancer could soon have access to a new targeted treatment on the NHS, following a decision by the National Institute for Health and Care Excellence. The tablet capivasertib, used alongside fulvestrant, has been approved for patients with hormone receptor-positive, HER2-negative breast cancer that has progressed after earlier endocrine treatment. Trials suggest capiversatib with fulvestrant on average gave patients an extra four months before their condition progressed compared to fulvestrant alone.